Literature DB >> 2301854

Airborne concentrations and particle size distribution of allergen derived from domestic cats (Felis domesticus). Measurements using cascade impactor, liquid impinger, and a two-site monoclonal antibody assay for Fel d I.

C M Luczynska1, Y Li, M D Chapman, T A Platts-Mills.   

Abstract

The recent development of a sensitive two-site monoclonal antibody immunoassay for the major cat allergen (Fel d I) has made it possible to make accurate measurements of airborne cat allergen using low volume samplers that do not disturb the room. Houses with cats had from 2 to 20 ng Fel d I/m3 air compared with less than 0.2 ng/m3 in houses without cats. Using a cascade impactor and a multistage liquid impinger, the particle size distribution of airborne Fel d I in nine houses was 75% on particle greater than or equal to 5 microns in diameter and 25% (range, 10 to 62%) on particles less than or equal to 2.5 microns. In a cat vivarium with 12 cats, the air contained 40 ng Fel d I/m3, but less than 2% was detected on particles less than or equal to 2.5 microns. The air exchange rate in the vivarium (approximately 15 changes/h) appears to be the major difference from domestic houses (less than 0.5 changes/h). Repeated studies in one house confirmed a very high proportion (approximately 60%) of Fel d I on small particles. During domestic cleaning, the levels of small particle allergen in this house approached those produced by a nebulizer for bronchial provocation, i.e., 40 ng/m3. These results show unequivocally that significant airborne Fel d I is associated with small particles, which remain airborne for long periods. These findings are strikingly different from previous results obtained with airborne dust mite allergen. The results provide an explanation for the distinctive rapid onset of asthma or rhinitis in patients allergic to cats and a basis for designing a policy to reduce airborne allergen in houses with cats.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2301854     DOI: 10.1164/ajrccm/141.2.361

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  37 in total

Review 1.  The role of allergens in the induction of asthma.

Authors:  Thomas A E Platts-Mills
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

Review 2.  Monitoring personal allergen exposure.

Authors:  T O'Meara; E Tovey
Journal:  Clin Rev Allergy Immunol       Date:  2000-06       Impact factor: 8.667

Review 3.  New approaches to environmental control.

Authors:  J W Vaughan; T A Platts-Mills
Journal:  Clin Rev Allergy Immunol       Date:  2000-06       Impact factor: 8.667

Review 4.  Allergen exposure and control.

Authors:  E R Tovey
Journal:  Exp Appl Acarol       Date:  1992-11       Impact factor: 2.132

Review 5.  Home Environmental Interventions for House Dust Mite.

Authors:  Jeffrey M Wilson; Thomas A E Platts-Mills
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jan - Feb

6.  High-dose allergen exposure leads to tolerance.

Authors:  Judith A Woodfolk
Journal:  Clin Rev Allergy Immunol       Date:  2005-02       Impact factor: 8.667

7.  Reply.

Authors:  Jeffrey M Wilson; Thomas A E Platts-Mills
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jul - Aug

8.  Fel d 1-airway inflammation prevention and treatment by co-immunization vaccine via induction of CD4+CD25-Foxp3+ Treg cells.

Authors:  Yechun Pei; Shuang Geng; Lin Liu; Fengxiang Yan; Hong Guan; Jian Hou; Yongfu Chen; Bin Wang; Xiaorong An
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

9.  Allergies in children.

Authors:  Z Chad
Journal:  Paediatr Child Health       Date:  2001-10       Impact factor: 2.253

10.  Parent report of pests and pets and indoor allergen levels in inner-city homes.

Authors:  Jean Curtin-Brosnan; Elizabeth C Matsui; Patrick Breysse; Meredith C McCormack; Nadia N Hansel; Emily S Tonorezos; Peyton A Eggleston; Dann L Williams; Gregory B Diette
Journal:  Ann Allergy Asthma Immunol       Date:  2008-11       Impact factor: 6.347

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.